IRWD Ironwood Pharmaceuticals (IRWD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001446847
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
99
13F, latest reported quarter
What the filings say about IRWD
Insiders, 180 days
-$658.5K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$377.4K
1 notice
Ironwood Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, IRONWOOD PHARMACEUTICALS INC insiders sold a net $658.5K of stock across 133 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Feb 24, 2026.
- The trade is 40.8% of the 313,680 shares held after it.
- 1 other insider sold within 30 days.
- 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PFO & PAO Silver Ronald sold about $578.1K of IRWD on Jul 7, 2026; 1 other insider sold within 30 days and 99 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 10, 2024.
- The trade is 8.6% of the 250,749 shares held after it.
- 1 other insider sold within 30 days.
- 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director McHugh Julie sold about $80.5K of IRWD on Jun 16, 2026; 1 other insider sold within 30 days and 99 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 9,188,635 shares held after it.
- 6 other insiders sold within 30 days.
- 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DENNER ALEXANDER J sold about $19.2K of IRWD on Mar 17, 2026; 6 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 73.1% of the 9,194,435 shares held after it.
- 6 other insiders sold within 30 days.
- 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DENNER ALEXANDER J sold about $20.5M of IRWD on Mar 17, 2026, the largest insider sale at the company on our record; 6 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 23, 2026.
- The trade is 7.1% of the 160,601 shares held after it.
- 6 other insiders sold within 30 days.
- 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Martini Gregory S. sold about $41.9K of IRWD on Feb 24, 2026; 6 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.133 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$658.5K over 180 days
below 58% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
99 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
-15.7% year over year
below 68% of Pharma & Biotech
Margin
8.1% net margin
more than 79% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.4% of the float short (float per yahoo 2026-10-26) · 6.2 days to cover · settled 2026-09-30
more than 69% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch IRWD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+114.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IRWD: institutional holders (13F)
13F holdings, latest reported quarter
17,788,557 sh
$74.9M
13,932,000 sh
$58.7M
9,188,635 sh
$38.7M
8,809,601 sh
$37.1M
8,683,803 sh
$36.6M
Congress trades in IRWD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
IRWD planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Shetzline Michael
Filed 2026-09-23
$377.4K
RONALD SILVER
Filed 2026-07-07
$560.2K
IRWD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Etf
$1.6M position · as of 2026-07-31
1.6%
Inspire Fidelis Multi Factor ETF
$2.0M position · as of 2026-05-31
1.0%
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$276.6K position · as of 2026-06-30
0.9%
Distillate Small/Mid Cash Flow ETF
$761.7K position · as of 2026-06-30
0.6%
Ultra-Small Company Fund
$572.5K position · as of 2026-06-30
0.6%
Franklin Small Cap Enhanced ETF
$678.5K position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $658.5K sold by insiders over 180 days, 99 funds added last quarter, $377.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
IRWD financials
Revenue growth
-15.7%
XBRL, annual
Net margin
8.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$389.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM IRWD
| FY Dec 2025 | $296.2M |
| FY Dec 2024 | $351.4M |
| FY Dec 2023 | $442.7M |
| FY Dec 2022 | $410.6M |
| FY Dec 2021 | $413.8M |
| Jun 2026 | $113.0M |
| Mar 2026 | $106.5M |
| Dec 2025 | $47.7M |
| Sep 2025 | $122.1M |
| Jun 2025 | $85.2M |
| Mar 2025 | $41.1M |
| Dec 2024 | $90.5M |
| Sep 2024 | $91.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+33.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM IRWD
| FY Dec 2025 | +8.1% |
| FY Dec 2024 | +0.3% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +42.6% |
| FY Dec 2021 | +127.7% |
| Jun 2026 | +45.4% |
| Mar 2026 | +38.3% |
| Dec 2025 | -4.8% |
| Sep 2025 | +32.8% |
| Jun 2025 | +27.7% |
| Mar 2025 | -90.9% |
| Dec 2024 | +2.5% |
| Sep 2024 | +4.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$185.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM IRWD
| FY Dec 2025 | $127.0M |
| FY Dec 2024 | $103.4M |
| FY Dec 2023 | $183.2M |
| FY Dec 2022 | $273.6M |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $74.6M |
| Sep 2025 | $47.6M |
| Jun 2025 | -$15.1M |
| Mar 2025 | $19.9M |
| Dec 2024 | $15.2M |
| Sep 2024 | $9.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity IRWD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.61x |
| FY Dec 2021 | 0.75x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.93x
TTM operating cash flow over LongTermDebt as filed 2025-09-30 (9 months older than the period end) (includes the current portion)
Cash flow to debt IRWD
| FY Dec 2025 | 0.64x |
| FY Dec 2024 | 0.52x |
| FY Dec 2023 | 0.46x |
| FY Dec 2022 | 0.69x |
| FY Dec 2021 | 0.58x |
| Jun 2026 | 0.93x |
| Mar 2026 | 0.56x |
| Dec 2025 | 0.64x |
| Sep 2025 | 0.34x |
| Jun 2025 | 0.15x |
| Mar 2025 | 0.39x |
| Dec 2024 | 0.52x |
| Sep 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity IRWD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +27.8% |
| FY Dec 2021 | +158.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+41.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets IRWD
| FY Dec 2025 | +6.4% |
| FY Dec 2024 | +0.2% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +15.7% |
| FY Dec 2021 | +62.7% |
| Jun 2026 | +41.4% |
| Mar 2026 | +26.8% |
| Dec 2025 | +6.4% |
| Sep 2025 | +7.3% |
| Jun 2025 | -2.1% |
| Mar 2025 | -8.4% |
| Dec 2024 | +0.2% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
invested capital is zero or negative
Return on invested capital IRWD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +44.8% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+129.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed IRWD
| FY Dec 2025 | +42.2% |
| FY Dec 2024 | +36.7% |
| FY Dec 2023 | -148.9% |
| FY Dec 2022 | +24.5% |
| FY Dec 2021 | +31.1% |
| Jun 2026 | +129.1% |
| Mar 2026 | +83.9% |
| Dec 2025 | +42.2% |
| Sep 2025 | +49.9% |
| Jun 2025 | +31.9% |
| Mar 2025 | +22.8% |
| Dec 2024 | +36.7% |
| Sep 2024 | +34.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
4.55x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing IRWD
| FY Dec 2025 | 25.92x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 12.77x |
| FY Dec 2021 | 3.61x |
| Jun 2026 | 5.47x |
| Mar 2026 | 5.85x |
| Dec 2025 | 25.92x |
| Sep 2025 | 8.73x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$698.7M
market value at close 2026-10-26 on 2026-07-31 shares, plus LongTermDebt as filed 2025-09-30 (9 months older than the period end) (includes the current portion), minus cash 2026-06-30
Enterprise value IRWD
| FY Dec 2025 | $532.3M |
| FY Dec 2024 | $819.4M |
| FY Dec 2023 | $2.1B |
| FY Dec 2022 | $1.6B |
| FY Dec 2021 | $1.7B |
| Jun 2026 | $813.4M |
| Mar 2026 | $551.4M |
| Dec 2025 | $532.3M |
| Sep 2025 | $271.9M |
| Jun 2025 | $223.0M |
| Mar 2025 | $328.5M |
| Dec 2024 | $819.4M |
| Sep 2024 | $768.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+32.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield IRWD
| FY Dec 2025 | +23.2% |
| FY Dec 2024 | +14.6% |
| FY Dec 2023 | +10.3% |
| FY Dec 2022 | +14.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | +26.8% |
| Mar 2026 | +19.6% |
| Dec 2025 | +23.2% |
| Sep 2025 | +31.8% |
| Jun 2025 | +25.7% |
| Mar 2025 | +33.0% |
| Dec 2024 | +14.6% |
| Sep 2024 | +18.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing IRWD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.01x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M |
| Operating income | $98.5M | $93.1M | -$945.4M | $250.3M |
| Net income | $24.0M | $880.0K | -$1.0B | $175.1M |
| EPS (diluted) | 0.15 | 0.01 | -6.45 | 0.96 |
| Operating cash flow | $127.0M | $103.5M | $183.4M | $273.8M |
| Cash | $215.5M | $88.6M | $92.2M | $656.2M |
| Long-term debt | n/a | $199.0M | $397.9M | $396.3M |
| Buybacks | n/a | n/a | n/a | $126.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
IRWD Stock Sonar score 6/7 axes
Find similar shapesCompareIRWD ranks highest on profitability (98th percentile) and financial health (92nd), and lowest on insider conviction (20th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
IRWD filings, in plain words
Are Ironwood Pharmaceuticals insiders buying or selling IRWD?
In the 180 days to 2026-10-28, Ironwood Pharmaceuticals insiders were net sellers, a net $658.5K across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of IRWD?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $377.4K of stock; the latest, by Shetzline Michael, was filed 2026-09-23.
Read the full summary
In the 180 days to 2026-10-28, Ironwood Pharmaceuticals insiders were net sellers of IRWD, a net $658.5K across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $377.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
